Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-1,3-galactosyltransferase 2 (B3GALT2)
- Target
- B3GALT2
- Molecular classification
- Enzyme (glycosyltransferase, specifically beta-1,3-galactosyltransferase), Type II membrane-bound glycoprotein
01
Overview
Beta-1,3-galactosyltransferase 2 (B3GALT2) is a membrane-bound enzyme belonging to the glycosyltransferase family that catalyzes the transfer of galactose from UDP-galactose to substrates with terminal beta-N-acetylglucosamine residues, thereby participating in the biosynthesis of carbohydrate chains on glycoproteins and glycolipids[1][8]. It plays a critical role in N-linked glycoprotein glycosylation and is involved in important cellular processes such as glycosaminoglycan metabolism and blood group antigen biosynthesis[1][8]. Mutations or dysfunction in the gene have been associated with rare disorders such as cornea plana and hyperparathyroidism, but the protein is not currently a major direct drug target and has limited evidence for clinical biomarker use[1][7][8].
- Other names
- Beta3Gal-T2Beta-1,3-GalTase 2UDP-galactose:2-acetamido-2-deoxy-D-glucose 3beta-galactosyltransferase 2UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2GLCT2BETA3GALT2beta-3-galt2beta3GalT2
02
Mechanism of action
Not applicable (no approved drugs directly targeting B3GALT2); mechanism would involve inhibition or modulation of glycosyltransferase enzymatic activity
03
Biological functions
N-acetyl-beta-D-glucosaminide beta-(1,3)-galactosyltransferase activityInvolved in N-linked glycoprotein glycosylationCarbohydrate chain biosynthesis for glycolipids and glycoproteinsGalactosylceramide biosynthetic processParticipates in blood group systems biosynthesisGlycosaminoglycan metabolism
04
Disease associations
Cornea planaHyperparathyroidism(Potential involvement in other glycosylation disorders and blood group phenotypes; evidence is primarily genetic/biochemical, not established as a major drug target)
05
Safety considerations
No specific safety concerns or therapeutic challenges are documented for targeting B3GALT2; general concerns for glycosyltransferase modulation could include alteration of glycoprotein/glycolipid function leading to systemic effects
06
Interacting drugs
None explicitly reported in available searches; not known as a direct drug target
07
Biomarkers
None explicitly reported as clinical biomarkers for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Beta-1,3-galactosyltransferase 2 (B3GALT2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beta-1,3-galactosyltransferase 2 (B3GALT2).